81
edits
Supply Chain Issues: Difference between revisions
Jump to navigation
Jump to search
→Common Supply Chain Challenges during the Pandemic
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities. | The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities. | ||
The situation exacerbates existing global health inequities.<ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst shortages | The situation exacerbates existing global health inequities.<ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst supply shortages, uncertain medical stocks and counterfeit medical essentials are global problems, developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacked access to certain essential medications. | ||
===Common Supply Chain Challenges during the Pandemic === | |||
Essential medicines and products experienced supply challenges during the Pandemic in connection with lockdowns and transportation issues, manufacturing challenges, and increased demand. | |||
==== Antibiotics ==== | |||
Penicillin and its derivatives. | |||
==== Critical Care and Anaesthesia==== | |||
Medications used in intensive care units (ICUs) for intubated patients and during surgical procedures. | |||
==== Sedatives and Pain Management Medications==== | |||
Opioid and standard non-opioid pain relievers. | |||
==== Ventilator Supplies==== | |||
Components and medications needed for ventilator use. | |||
==== Inhalers==== | |||
Asthma and COPD medications, such as albuterol inhalers. | |||
==== Personal protective equipment (PPE)==== | |||
Masks, N95 respirators and surgical masks crucial for healthcare workers. | |||
====Hand Sanitiser==== | |||
Medical-grade hand sanitisers and alcohol-based hand sanitiser recommended by the World Health Organisation (WHO) for their effectiveness in killing bacteria. The extreme shortage led some distilleries to start production of their own brands of hand sanitiser, and a relaxation in regulation to allow for rapid production and distribution. | |||
===Ongoing Supply Chain Challenges=== | ===Ongoing Supply Chain Challenges=== | ||
| Line 45: | Line 70: | ||
''' | ''' | ||
Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production. | Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production. | ||
===Long-term Changes in Medical Supply Chains=== | |||
Different countries responded to the pandemic with varying levels of leadership, governance, and preparedness. Public health measures and government communication also differed significantly. The pandemic is leading to changes in how supplies are produced and distributed based on what was learned from these varied approaches. Regulatory frameworks are adapting to factor in precaution and to allow more flexibility in future crises. | |||
There is also learning from from successful initiatives, such as Singapore’s national stockpile of PPE and medical products to last for up to 6 months, drawing on the lessons learned when responding to the SARS (Severe Acute Respiratory Syndrome) outbreak in 2003 <ref>Chua, A. Q. et al. Health system resilience in managing the COVID-19 pandemic: lessons from Singapore. BMJ Glob. Health 5, e003317 (2020). https://gh.bmj.com/content/5/9/e003317 </ref> | |||
==Citations== | ==Citations== | ||
<references/> | <references/> | ||